Takeda, Sarepta double down on a biotech partner's platform to engineer better AAV capsids by mapping out their structure

Amber Tong

When Aravind Asokan and Mavis Agbandje-McKenna first pulled together their respective research at the University of North Carolina-Chapel Hill and the University of Florida on …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Takeda, Sarepta double down on a biotech partner's platform to engineer better AAV capsids by mapping out their structure

Amber Tong

Sign up to read this article for free.

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sana narrows focus again to zero in on diabetes and autoimmune disease

Vertex makes money from sickle cell therapy Casgevy

The election is Tuesday. What’s at stake for the pharma industry?

Is there room for MASH drugs in a GLP-1 world?

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Take­da, Sarep­ta dou­ble down on a biotech part­ner's plat­form to en­gi­neer bet­ter AAV cap­sids by map­ping out their struc­ture

Amber Tong

Sign up to read this article for free.

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Sana nar­rows fo­cus again to ze­ro in on di­a­betes and au­toim­mune dis­ease

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

The elec­tion is Tues­day. What’s at stake for the phar­ma in­dus­try?

Is there room for MASH drugs in a GLP-1 world?

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Takeda, Sarepta double down on a biotech partner's platform to engineer better AAV capsids by mapping out their structure

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sana narrows focus again to zero in on diabetes and autoimmune disease

Vertex makes money from sickle cell therapy Casgevy

The election is Tuesday. What’s at stake for the pharma industry?

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks